Aspirin for primary prevention of myocardial infarction: What is the evidence?

Tissa Kappagoda, Ezra A Amsterdam

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: Aspirin has been advocated as a primary prevention measure for myocardial infarction (MI) for more than 2 decades. While several meta-analyses have supported this view, others have differed. All these analyses have focused on data from 6 major clinical trials. METHODS: We have provided a detailed analysis of the methods used in the individual trials (n = 6) included in the published meta-analyses. RESULTS: The major limitations of the meta-analyses relate to inclusion of heterogeneous trials characterized by widely differing study cohorts, absence of true control groups, lack of identification of silent MIs, failure to specify type of stroke, and inadequate information on management of conventional cardiac risk factors such as hypertension and hyperlipidemia. These issues preclude meaningful conclusions on the effects of aspirin in primary prevention of MI. CONCLUSIONS: This analysis does not support a general recommendation for the use of aspirin for primary prevention of MI and also suggests that effective management of risk factors in accordance with current guidelines may attenuate any potential benefit from aspirin with respect to MI. However, there may be a modest benefit in postmenopausal women with respect to stroke.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalJournal of Cardiopulmonary Rehabilitation and Prevention
Volume32
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Primary Prevention
Aspirin
Myocardial Infarction
Meta-Analysis
Stroke
Information Management
Social Identification
Hyperlipidemias
Cohort Studies
Clinical Trials
Guidelines
Hypertension
Control Groups

Keywords

  • aspirin
  • myocardial infarction
  • primary prevention

ASJC Scopus subject areas

  • Rehabilitation
  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine

Cite this

Aspirin for primary prevention of myocardial infarction : What is the evidence? / Kappagoda, Tissa; Amsterdam, Ezra A.

In: Journal of Cardiopulmonary Rehabilitation and Prevention, Vol. 32, No. 1, 01.2012, p. 1-8.

Research output: Contribution to journalArticle

@article{f3bc9e9ab6e24c499ad10f9f6b44fc5f,
title = "Aspirin for primary prevention of myocardial infarction: What is the evidence?",
abstract = "BACKGROUND: Aspirin has been advocated as a primary prevention measure for myocardial infarction (MI) for more than 2 decades. While several meta-analyses have supported this view, others have differed. All these analyses have focused on data from 6 major clinical trials. METHODS: We have provided a detailed analysis of the methods used in the individual trials (n = 6) included in the published meta-analyses. RESULTS: The major limitations of the meta-analyses relate to inclusion of heterogeneous trials characterized by widely differing study cohorts, absence of true control groups, lack of identification of silent MIs, failure to specify type of stroke, and inadequate information on management of conventional cardiac risk factors such as hypertension and hyperlipidemia. These issues preclude meaningful conclusions on the effects of aspirin in primary prevention of MI. CONCLUSIONS: This analysis does not support a general recommendation for the use of aspirin for primary prevention of MI and also suggests that effective management of risk factors in accordance with current guidelines may attenuate any potential benefit from aspirin with respect to MI. However, there may be a modest benefit in postmenopausal women with respect to stroke.",
keywords = "aspirin, myocardial infarction, primary prevention",
author = "Tissa Kappagoda and Amsterdam, {Ezra A}",
year = "2012",
month = "1",
doi = "10.1097/HCR.0b013e31822f1aa7",
language = "English (US)",
volume = "32",
pages = "1--8",
journal = "Journal of Cardiopulmonary Rehabilitation and Prevention",
issn = "1932-7501",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Aspirin for primary prevention of myocardial infarction

T2 - What is the evidence?

AU - Kappagoda, Tissa

AU - Amsterdam, Ezra A

PY - 2012/1

Y1 - 2012/1

N2 - BACKGROUND: Aspirin has been advocated as a primary prevention measure for myocardial infarction (MI) for more than 2 decades. While several meta-analyses have supported this view, others have differed. All these analyses have focused on data from 6 major clinical trials. METHODS: We have provided a detailed analysis of the methods used in the individual trials (n = 6) included in the published meta-analyses. RESULTS: The major limitations of the meta-analyses relate to inclusion of heterogeneous trials characterized by widely differing study cohorts, absence of true control groups, lack of identification of silent MIs, failure to specify type of stroke, and inadequate information on management of conventional cardiac risk factors such as hypertension and hyperlipidemia. These issues preclude meaningful conclusions on the effects of aspirin in primary prevention of MI. CONCLUSIONS: This analysis does not support a general recommendation for the use of aspirin for primary prevention of MI and also suggests that effective management of risk factors in accordance with current guidelines may attenuate any potential benefit from aspirin with respect to MI. However, there may be a modest benefit in postmenopausal women with respect to stroke.

AB - BACKGROUND: Aspirin has been advocated as a primary prevention measure for myocardial infarction (MI) for more than 2 decades. While several meta-analyses have supported this view, others have differed. All these analyses have focused on data from 6 major clinical trials. METHODS: We have provided a detailed analysis of the methods used in the individual trials (n = 6) included in the published meta-analyses. RESULTS: The major limitations of the meta-analyses relate to inclusion of heterogeneous trials characterized by widely differing study cohorts, absence of true control groups, lack of identification of silent MIs, failure to specify type of stroke, and inadequate information on management of conventional cardiac risk factors such as hypertension and hyperlipidemia. These issues preclude meaningful conclusions on the effects of aspirin in primary prevention of MI. CONCLUSIONS: This analysis does not support a general recommendation for the use of aspirin for primary prevention of MI and also suggests that effective management of risk factors in accordance with current guidelines may attenuate any potential benefit from aspirin with respect to MI. However, there may be a modest benefit in postmenopausal women with respect to stroke.

KW - aspirin

KW - myocardial infarction

KW - primary prevention

UR - http://www.scopus.com/inward/record.url?scp=84855354552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855354552&partnerID=8YFLogxK

U2 - 10.1097/HCR.0b013e31822f1aa7

DO - 10.1097/HCR.0b013e31822f1aa7

M3 - Article

C2 - 21946421

AN - SCOPUS:84855354552

VL - 32

SP - 1

EP - 8

JO - Journal of Cardiopulmonary Rehabilitation and Prevention

JF - Journal of Cardiopulmonary Rehabilitation and Prevention

SN - 1932-7501

IS - 1

ER -